Royal Bank Of Canada Assembly Biosciences, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.65 - $1.25 $354 - $682	546 New	546 $0
Q2 2023 Aug 14, 2023	BUY	$0.81 - $1.15 $268 - $380	331 New	331 $0
Q3 2022 Nov 14, 2022	BUY	$1.7 - $2.34 $317 - $437	187 New	187 $0
Q1 2022 May 16, 2022	SELL	$1.46 - $2.45 $42 - $71	-29 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.13 - $3.46 $61 - $100	29 New	29 $0

Q3 2021 Nov 15, 2021	SELL	$3.14 - $3.9 $32,401 - $40,244	-10,319 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$3.8 - $4.56 $39,212 - $47,054	10,319 New	10,319 $40,000

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $665M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.